ResMed’s fair value estimate has been trimmed from US$296.53 to US$288.21, a reduction of about 2.8% that signals a more cautious stance on what analysts are willing to pay for the shares. This shift ...
Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to ...
Resmed said its Chief Financial Officer will retire in May and announced plans to acquire a startup with an FDA de novo ...
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 ...
By Bageshri Banerjee April 30 (Reuters) - Medical device maker ResMed beat third‑quarter profit estimates on Thursday, driven by strong demand for its medical devices, while appointing Aaron Bloomer ...
Resmed will buy Noctrix Health, the Pleasanton, Calif.-based developer of the Nidra Tonic Motor Activation therapy for ...
Medical device company ResMed (NYSE:RMD) will be announcing earnings results this Thursday afternoon. Here’s what to look for ...
SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal third-quarter profit of $398.7 million. On a per-share basis, the San Diego-based company said it had profit of $2.74.
Resmed Inc () has held its Q3 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for sma ...
Q3 fiscal 2026 Management View “We delivered another set of strong results, including 11% growth in headline revenue or 8% growth on a constant currency basis… resulting in 21% growth in non-GAAP ...
Resmed reported revenue increased by 11% to $1.4 billion for the third quarter fiscal year 2026. Other financial results: GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.
The Resmed CDI (AX: RMD) share price is in focus today after the company posted third-quarter revenue up 11% to US$1.43 ...